ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Populations of endometrial and endometriotic epithelial cells also harbor multiple cancer driver mutations, such as KRAS, which may be associated with the establishment of pelvic endometriosis or ovarian cancer.
|
30994890 |
2019 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Preliminary evidence of clinical activity was observed with gedatolisib plus PD-0325901 in patients with ovarian cancer (three partial responses, n = 5) or endometrial cancer (one partial response, n = 1) and KRAS mutations.
|
29067643 |
2017 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
No statistically significant association was found between the incidence of KRAS mutations and histopathological type of ovarian tumors.
|
28992761 |
2017 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Reintroducing KRAS rescued the inhibitory effects exerted by miR-613 on ovarian cancer cell proliferation and invasion.
|
26631045 |
2016 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
VEGF concentrations in ascites significantly increased in c-MYC-induced ovarian cancer, whereas the concentrations of inflammatory cytokines in ascites were significantly high in KRAS-induced ovarian cancer and were accompanied by an increased number of neutrophils in ascites.
|
27483433 |
2016 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results define the RAS/MEK/DNMT1 pathway as a determinant of sensitivity to DNA methyltransferase inhibition, specifically implicating KRAS status as a biomarker of drug response in ovarian cancer.
|
25968887 |
2015 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Together, REDD1 and p-AKT over-expression may serve as a prognostic biomarker in OC, but KRAS mutations and REDD1 protein over-expression were not correlated in OC.
|
25337238 |
2014 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genetic profiles were constructed for 75 SB and LGS ovarian tumors to determine BRAF and KRAS mutation status.
|
22930283 |
2013 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.
|
22662244 |
2012 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
|
21975775 |
2011 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Recently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families.
|
20676756 |
2011 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
CTD_human |
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
|
21372221 |
2011 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
An assay for the single-nucleotide polymorphism (SNP), rs61764370, has recently been commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with family histories of the disease. rs67164370 is in a 3'-UTR miRNA binding site of the KRAS oncogene and is a candidate for epithelial ovarian cancer (EOC) susceptibility.
|
21385923 |
2011 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our findings strongly support the hypothesis that the KRAS-variant is a genetic marker for increased risk of developing OC, and they suggest that the KRAS-variant may be a new genetic marker of cancer risk for HBOC families without other known genetic abnormalities.
|
20647319 |
2010 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
|
19358724 |
2009 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
|
19047918 |
2009 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the KRAS gene in ovarian tumors.
|
19995707 |
2009 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
We found no evidence of disease association for SNPs in BRAF, KRAS, ERBB2 and PIK3CA when OC was considered as a single disease phenotype; but after stratification by histological subtype, we found borderline evidence of association for SNPs in KRAS and BRAF with mucinous OC and in ERBB2 and PIK3CA with endometrioid OC.
|
19240718 |
2009 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Profound growth inhibition and apoptosis were observed in CI-1040-treated cancer cells with mutations in either KRAS or BRAF in comparison with the ovarian cancer cells containing wild-type sequences.
|
19018267 |
2008 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
|
17910045 |
2008 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Profound growth inhibition and apoptosis were observed in CI-1040-treated cancer cells with mutations in either KRAS or BRAF in comparison with the ovarian cancer cells containing wild-type sequences.
|
19018267 |
2008 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The identical KRAS mutation was detected in all of the analyzed components of the primary ovarian tumors in 4 cases.
|
18779727 |
2008 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
|
17332249 |
2007 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
|
15696205 |
2005 |
ovarian neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Somatic PTPN11 mutations in childhood acute myeloid leukaemia.
|
15842656 |
2005 |